Claim: Sleep apnea increases cardiovascular risk through a gut bile acid receptor called FXR. A new UCSD study found that blocking this receptor prevented arterial plaque buildup in mice with sleep apnea-like conditions.

First requested: June 15, 2026 at 10:44 AM
80%

IsItCap Score

Truth Potential Meter

Very Credible

AI consensusWeak

Grader consensus is weak.
Range 50%–95% (spread Δ45).
The graders diverge. Treat the combined score as uncertain and read the sources carefully.
Read analysis summary

OpenAI Grade

0%
20%
40%
60%
80%
85%

Perplexity Grade

0%
20%
40%
60%
80%
95%

Google Gemini Grade

0%
20%
40%
60%
80%
50%
Shareable summary
Verdict: Questionable
  • No human clinical trials yet confirm FXR inhibition reduces cardiovascular risk in sleep apnea patients.
  • Findings are limited to mouse models; biological differences may affect applicability to humans.
/r/sleep-apnea-fxr-cardiovascular-risk

Analysis Summary

The claim that sleep apnea increases cardiovascular risk through the FXR receptor is mostly true. Research from UCSD supports this, showing that blocking FXR significantly reduced arterial plaque buildup in mice with sleep apnea-like conditions. This finding aligns with the understanding that FXR plays a role in cardiovascular health related to sleep apnea. However, some alternative sources may dispute the extent of this relationship, suggesting that more research is needed to fully understand the implications for human health. The models diverge sharply — treat this as higher-uncertainty. Perplexity comes in highest (95%), while Gemini is lowest (50%). OpenAI expresses higher confidence than Gemini on this claim. While the evidence strongly supports the claim regarding the role of FXR in cardiovascular risk associated with sleep apnea, there is a lack of direct human studies to confirm these findings. Some experts may argue that animal studies do not always translate to human physiology, which could affect the applicability of these results. However, the absence of contradicting evidence in the provided sources strengthens the claim's validity, even if some nuances remain unaddressed.
Jump to source analysis

Source quality

Truth (from sources)8.00 / 10
Source reliability7.00 / 10
Source independence6.00 / 10

Claim checks

Fits established facts8.00 / 10
Logical consistency8.00 / 10
Expert consensus7.00 / 10
Related fact checks

Source Analysis

Common arguments
Supporting the claim
  • Peer-reviewed study shows FXR deficiency abolished atherosclerosis increase in mice with sleep apnea-like hypoxia.
  • UCSD-led research confirms disabling FXR sharply reduced plaque buildup in ApoE-/- mice under IHC conditions.
  • Multiple sources link FXR to gut microbiome shifts and arterial plaque reduction in sleep apnea models.
Against the claim
  • No human clinical trials yet confirm FXR inhibition reduces cardiovascular risk in sleep apnea patients.
  • Findings are limited to mouse models; biological differences may affect applicability to humans.
  • Mechanism involves gut microbiome, which varies widely between individuals, potentially limiting generalizability.

Mainstream Sources

Publication

pmc.ncbi.nlm.nih.gov

Title

Farnesoid X receptor-dependent microbiome-bile acid signaling mediates obstructive sleep apnea-induced atherosclerosis

Summary

Peer-reviewed article reporting that intermittent hypoxia/hypercapnia, a hallmark of obstructive sleep apnea, increased aortic atherosclerosis in ApoE-/- mice, and that FXR deficiency abolished this increase.

Source details

Type: Official
Primary Data

URL

Visit Source

Publication

sciencedaily.com

Title

Sleep apnea's hidden heart disease trigger found in the gut

Summary

ScienceDaily coverage of the UCSD-led mouse study stating that disabling FXR sharply reduced plaque buildup in sleep apnea-like conditions and may open new treatment approaches.

Source details

Type: Aggregator
Secondary Reporting

URL

Visit Source

Publication

neurosciencenews.com

Title

Link Between Gut Microbes and Sleep Apnea Discovered

Summary

Popular science report on the same UCSD work describing FXR as a therapeutic target and noting reduced arterial plaque when the receptor was removed in mice.

Source details

Type: Blog
Secondary Reporting

URL

Visit Source

Alternative Sources

Publication

N/A

Title

None found in the provided results

Summary

No provided source directly contradicts the core claim that FXR deficiency reduced atherosclerosis in a mouse sleep apnea model.

Source details

—

URL

Visit Source

Analysis Breakdown

True/False Spectrum (8.0)Source Credibility (7.0)Bias Assessment (6.0)Contextual Integrity (8.0)Content Coherence (8.0)Expert Consensus (7.0)73%

How to read the breakdown

Weakest areas
Independence6.0/10Source reliability7.0/10
  • Truth: how well sources support the core claim.
  • Source reliability: whether the sources have a strong track record.
  • Independence: whether coverage looks one-sided or recycled.
  • Context: missing details (timeframe, definitions, scope) that change meaning.
  • Tip: if graders disagree, rely more on the summary + sources than the single number.

Detailed AnalysisPremium Feature

Get an in-depth analysis of content accuracy, source credibility, potential biases, contextual factors, claim origins, and hidden perspectives.

Create a free account to unlock premium features.

Methodology